**ORIGINAL ARTICLE** 

# Assessment of cardiac autonomic functions by heart rate variability in patients with restless leg syndrome

# Huzursuz bacak sendromlu hastalarda kalp otonom fonksiyonlarının kalp hızı değişkenliği ile incelenmesi

#### Abdülmelik Yıldız, M.D.,<sup>1</sup> Cennet Yıldız, M.D.,<sup>2</sup> Ahmet Karakurt, M.D.<sup>3</sup>

<sup>1</sup>Department of Cardiology, Medical Park Hospital, İstanbul, Turkey <sup>2</sup>Department of Cardiology, TEKDEN Hospital, İstanbul, Turkey <sup>3</sup>Department of Cardiology, Kafkas University Faculty of Medicine, Kars, Turkey

#### ABSTRACT

**Objective:** The aim of the present study was to investigate cardiac autonomic effects in restless leg syndrome (RLS) using heart rate variability (HRV).

**Methods:** A total of 35 patients with RLS and 35 healthy individuals were enrolled in the study. The severity of RLS symptoms was assessed using the International Restless Legs Syndrome Study Group rating scale (IRLS). The correlation between the severity of RLS symptoms and HRV parameters measured on an electrocardiogram was analyzed.

**Results:** There were no statistically significant differences between the 2 groups with respect to age, gender, or body mass index. The mean heart rate was 85±7.1 bpm in the RLS group compared with 79.6±5.5 bpm in the control group (p=0.001). The standard deviation (SD) of all normal to normal (NN) intervals (SDNN), the mean of the deviation of 5-minute NN intervals over the entire recording (SDNN index), and the SD of the average NN intervals calculated over a 5-minute period of the entire recording (SDANN) were significantly lower in the RLS group compared with the control group (p<0.05 for all). There were no statistically significant differences between the 2 groups in the square root of the mean squared differences of successive NN intervals (RMSSD) and the proportion of adjacent RR intervals differing by >50 milliseconds in the 24-hour recording (pNN50) values (p=0.119 and p=0.07, respectively). In patients with RLS, the low frequency (LF) power and LF/ high frequency (HF) ratio were significantly higher than those in the control group (2248.6±245.6 vs 712.1±346.3, 10.7±3.7 vs 2.9±1.8; p<0.0001 and p<0.0001, respectively). Compared with the control group, the RLS group had lower values for HF power, but the difference was not statistically significant (p=0.07). The severity of RLS symptoms was negatively correlated with the SDNN, SDANN index, and pNN50 (r=-0.453 and p=0.009, r=-0.340 and p=0.046, r=-0.446 and p=0.007, respectively), and positively correlated with LF power (r=0.681 and p<0.0001).

*Conclusion:* The study data demonstrated that cardiac autonomic impairment is associated with RLS.

# ÖZET

**Amaç:** Bu çalışmada huzursuz bacak sendromlu (HBS) hastalarda kalp hızı değişkenliğini (KHD) inceleyerek kalp otonom fonksiyonlarını araştırmayı amaçladık.

**Yöntemler:** HBS tanısı konulan 35 hasta ve benzer özelliklere sahip 35 sağlıklı birey çalışmaya alındı. HBS semptomlarının şiddeti Uluslararası Huzursuz Bacak Çalışma Grubu Şiddeti Ölçeği kullanılarak değerlendirildi. HBS semptom şiddeti ve KHD parametreleri arasındaki ilişki değerlendirildi.

Bulgular: Yaş, cinsiyet veya vücut kitle indeksi açısından iki grup arasında istatistiksel açıdan anlamlı farklılıklar yoktu. HBS grubunda ortalama kalp atım hızı 85±7.1 /dk iken kontrol grubunda 79.6±5.5 /dk idi (p=0.001). Kontrol grubuna göre tüm normal değerler arası aralıkların (NN) standart sapması (SSNN), tüm kayıt süresince hesaplanmış 5-dakikalık NN aralıklarının ortalama sapması (SSNN indeksi) ve yine tüm kayıt süresince bir 5-dakikalık zaman diliminde ortalama NN aralıklarının hesaplanmış SS'si (SSANN) HBS grubunda anlamlı derecede daha düsüktü (tümü icin p<0.05). İki grup arasında ardışık NN aralıklarının ortalama kare farklılıklarının kare kökü (RMSSD) ve 24 saatlik kayıt boyunca 50 milisaniyeden daha uzun süre fark eden bitisik RR aralıklarının oranı (pNN50) açısından fark yoktu (sırasıyla, p=0.119 ve p=0.07). HBS hastalarında düşük frekans (DF)/yüksek frekans (YF) oranı kontrol grubuna göre anlamlı derecede daha yüksek idi (sırasıyla, 2248.6±245.6 ve 712.1±346.3, 10.7±3.7 ve 2.9±1.8; p<0.0001 ve p<0.0001). Kontrol grubuyla karşılaştırıldığında HBS grubunda DF güc değerleri daha düşük olmasına rağmen farklılık istatistiksel açıdan anlamlı değildi (p=0.07). HBS semptomlarının şiddet derecesi SDNNN, SDANN indeksi ve pNN50 ile negatif (sırasıyla, r=-0.453 ve p=0.009, r=-0.340 ve p=0.046, r=-0.446 ve p=0.007) ve YF ile pozitif bir korelasyon göstermekteydi (r=0.681 ve p<0.0001).

**Sonuç:** Çalışma verileri kardiyak otonomik bozukluğun HBS ile ilişkili olduğunu göstermiştir.

Received: July 05, 2017 Accepted: January 22, 2018 Correspondence: Dr. Cennet Yıldız. Konaklar Mahallesi., Org. İzzettin Aksalur Caddesi, Seebrig 1/11, Beşiktaş, İstanbul. Tel: +90 212 - 517 67 14 e-mail: cennet\_yildiz@live.com © 2018 Turkish Society of Cardiology



**R**estless leg syndrome (RLS) was first described by Sir Thomas Willis in 1672.<sup>[1]</sup> Swedish neurologist Ekbom systematically described the disorder and named it RLS in 1945.<sup>[2]</sup> It is a common condition, consisting of a strong urge to move the legs that occurs during inactivity and at night. It causes sleep disturbance and has a negative impact on quality of life. The pathophysiology of RLS is largely unknown. Abnormalities of the dopaminergic system have been suggested as a possible etiology.<sup>[3]</sup> The prevalence of RLS has been reported to be between 5% and 10%.<sup>[4]</sup> Symptoms are most common in lower limbs, but may also involve the arms or other parts of the body.<sup>[5-7]</sup>

Patients with RLS have significantly more autonomic complaints than the general population, such as sialorrhea, constipation, early abdominal fullness, lightheadedness when standing, and heat intolerance.<sup>[8]</sup> Additionally, significant elevations in nocturnal blood pressure and pulse rate, and an increased prevalence and incidence of hypertension, cardiovascular disease, and cerebrovascular disease suggestive of autonomic dysfunction have been found in RLS patients.<sup>[9]</sup> Although several epidemiological studies have demonstrated an increased risk for cardiovascular disease in RLS,<sup>[10,11]</sup> relatively few studies have investigated the underlying mechanisms involved in cardiovascular disease.

Heart rate variability (HRV) reliably reflects cardiac autonomic balance and indirectly measures sinoatrial node functions.<sup>[12]</sup> It is known that a decrease in HRV is the earliest sign of cardiac autonomic neuropathy.<sup>[12-14]</sup> The present study was carried out (1) to investigate cardiac autonomic function by assessing HRV in patients with RLS and (2) to determine if there was a correlation between RLS symptoms and cardiac autonomic dysfunction in these patients.

#### **METHODS**

Thirty-five patients with RLS and 35 age- and gendermatched healthy individuals were enrolled in the study. Patients with RLS who were followed up at our neurology clinic were enrolled in the study. The diagnosis of RLS was made on the basis of clinical symptoms using the revised International Restless Legs Syndrome Study Group (IRLSSG) criteria published in 2012.<sup>[15]</sup>

The severity of RLS symptoms was assessed by using the IRLSSG rating scale (IRLS) summed score levels of mild (0-10), moderate (11-20), severe (21-

30) and very severe (31–40).<sup>[16]</sup>

Patients who had been receiving treatment for RLS and had received who prescriptions for antidepressants, antiarrhythmic drugs, beta-blockers, calcium channel blockers, or with a history of valve disease or replacepacemaker ment. implantation, atrial

Abbreviations:		
BMI	Body mass index	
HF	High frequency	
HRV	Heart rate variability	
LF	Low frequency	
NN	Normal to normal interval	
pNN50	Proportion of adjacent RR	
	intervals differing by >50 ms	
	in a 24-hour recording	
RLS	Restless leg syndrome	
RMSSD	Square root of the mean squared	
	differences of successive NN	
	intervals	
SD	Standard deviation	
SDANN	SD of the average NN intervals	
	calculated over a 5-minute	
	period of the entire recording	
SDNN	SD of all NN intervals	

fibrillation, arrhythmias, thyroid disease, diabetes mellitus, hypertension, chronic renal failure, liver disease, ischemic heart disease, sleep apnea syndrome, congestive heart failure, stroke, or neurological disorder were excluded from the study. The study was approved by the ethics committee and was performed according to the Declaration of Helsinki. Written informed consent was obtained from all of the patients.

Twenty-four hour Holter electrocardiogram recordings were obtained using 3-channel digital recorders (Cardioscan Premier Version 12; DM Systems Co., Ltd. Beijing, China). Recordings lasting more than 22 hours and of sufficient quality for evaluation were included in the analysis. HRV was measured using the algorithms of the commercial device. Time domain HRV indices were analyzed with a statistical method in which the square root of the mean squared differences of successive normal to normal (NN) intervals (RMSSD), the standard deviation (SD) of all NN intervals (SDNN), the mean of the deviation of the 5-minute NN intervals over the entire recording (SDNN index), the SD of the average NN intervals calculated over a 5-minute period of the entire recording (SDANN), and the proportion of adjacent RR intervals differing by >50 milliseconds in the 24-hour recording (pNN50) were measured. Spectral analysis of HRV included total power, which represents the variability of the entire signal and was obtained by summing the powers of each frequency band, a high frequency (HF) component (0.15-0.40 Hz), and a low frequency (LF) component (0.04-0.15 Hz). The LF/ HF power was calculated for all of the participants. Sympathetic and parasympathetic activities were automatically calculated through an analysis program. All of the measurements were performed according to the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.<sup>[12]</sup>

# **Statistical analysis**

Continuous variables were expressed as mean±SD, and categorical variables were expressed as percentages. Statistical analyses were performed by using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA). The mean values for the RLS patients and the controls were compared using the 2-sample t-test. The correlations between the observed variables were examined with Pearson's correlation test. A p value <0.05 was considered statistically significant.

# RESULTS

Table 1 illustrates the clinical characteristics of the study groups. There were no statistically significant differences between the 2 groups with respect to age, gender, body mass index (BMI), smoking, blood pressure, ejection fraction, levels of fasting blood glucose, creatinine, hemoglobin, or thyroid-stimulating hormone.

The mean heart rate was  $85\pm7.1$  bpm in the RLS group compared with 79.6±5.5 bpm in the control group (p=0.001). The SDNN, SDANN, and SDNN

index were significantly lower in the RLS group compared with the control group (p<0.05 for all). Likewise, the RMSSD and the pNN50 decreased in the patient group, but not to a statistically significant degree (p=0.119 and 0.07 respectively). In patients with RLS, the LF power and the LF/HF ratio were significantly higher than those in the control group (2248.6±245.6 vs. 712.1±346.3, 10.7±3.7 vs. 2.9±1.8; p<0.0001 and p<0.0001 respectively). Compared with the control group, the RLS group had lower HF power values, but the difference was not statistically significant (p=0.07). The HRV parameters of the patients are shown in Table 2.

The RLS group was found to have greater sympathetic activity and decreased parasympathetic activity compared with the control group ( $95.04\%\pm1.2$  vs  $91.1\%\pm4.02$ ,  $4.9\%\pm1.2$  vs.  $8.8\%\pm4.0$ ; p<0.0001 for both). The ratio of sympathetic and parasympathetic activity was significantly greater in the patient group compared with the control group ( $20.1\pm4.4$  and  $13.3\pm7.6$ ; p<0.0001).

The severity of RLS symptoms was negatively correlated with the SDNN, SDANN index, and pNN50 (r=-0.453 and p=0.009, r=-0.340 and p=0.046, r=-0.446 and p=0.007, respectively) and positively correlated with LF power (r=0.681 and p<0.0001). Table 3 shows the correlations between the IRLS summed score and HRV parameters.

Table 1. Clinical characteristics of the patients					
	Restless leg syndrome	Control	р		
	(n=35)	(n=35)			
Age (years)	41.9±8.8	43.3±9.9	0.527		
Gender (female), n (%)	19 (54.2)	18 (51.4)	0.892		
Smoking, n (%)	15 (42.8)	14 (40)	0.894		
Systolic blood pressure (mm Hg)	132.4±14.5	128.5±16.4	0.252		
Diastolic blood pressure (mm Hg)	85.4±6.4	81.9±7.5	0.158		
Body mass index (kg/m²)	28.7±3.4	27.3±4.1	0.875		
Fasting blood glucose (mg/dL)	101±11	97±13	0.411		
Creatinine (mg/dL)	0.86±0.11	0.83±0.12	0.365		
Ejection fraction (%)	65±9	63±7	0.455		
Hemoglobin (g/dL)	12.1	13.1	0.09		
Thyroid-stimulating hormone (µIU/mL)	1.71±0.85	1.81±0.9	0.49		
Heart rate	85±7.1	79.6±5.5	0.001		
Recording time (hours)	23.1±1.1	23.3±1.2	0.97		

Table 1. Clinical characteristics of the patient

Table 2. Heart rate variability parameters of the patients						
Restless leg syndrome group	Control group	p				
133.7±20.1	144.8±23.9	0.04				
119.1±18.9	132.9±23.7	0.009				
52±10.5	57.4±10.8	0.03				
28.2±7.2	31.4±9.4	0.119				
7.9±1.9	9.8±5.4	0.07				
2248.6±245.6	712.1±346.3	<0.0001				
229.0±68.8	278.2±144.8	0.07				
10.7±3.7	2.9±1.8	<0.0001				
95.04±1.2	91.1±4.02	<0.0001				
4.9±1.2	8.8±4.0	<0.0001				
20.1±4.4	13.3±7.6	<0.0001				
	Restless leg syndrome group   133.7±20.1   119.1±18.9   52±10.5   28.2±7.2   7.9±1.9   2248.6±245.6   229.0±68.8   10.7±3.7   95.04±1.2   4.9±1.2	Restless leg syndrome group   Control group     133.7±20.1   144.8±23.9     119.1±18.9   132.9±23.7     52±10.5   57.4±10.8     52±10.5   57.4±10.8     28.2±7.2   31.4±9.4     7.9±1.9   9.8±5.4     2248.6±245.6   712.1±346.3     229.0±68.8   278.2±144.8     10.7±3.7   2.9±1.8     95.04±1.2   91.1±4.02     4.9±1.2   8.8±4.0				

pNN50: The proportion of adjacent RR intervals differing by >50 ms in the 24-hour recording; RMSSD: The square root of the mean squared differences of successive normal to normal intervals; SDANN: The standard deviation of the average normal to normal intervals calculated over a 5-minute period of the entire recording; SDNN: The standard deviation of all normal to normal intervals; SDNN index: The mean of the deviation of the 5-minute normal to normal intervals over the entire electrocardiogram recording.

## DISCUSSION

We investigated cardiac autonomic functions with regard to RLS and examined whether there existed an underlying cardiac autonomic dysfunction. In our study, we evaluated HRV metrics in time and frequency domain analysis in patients with RLS and without coexisting diseases. The study data indicated that cardiac autonomic impairment was associated with RLS. The time domain markers of SDNN. SDANN, and SDNN index were found to be significantly lower in patients with RLS, which might reflect a predominant sympathetic stimulation of the heart. Compared with the controls, the RLS patients had a

Table 3. Correlations between IRLS summed score and **HRV** parameters

	r	р
SDNN (ms)	-0.453	0.009
SDANN (ms)	-0.340	0.046
pNN50 (%)	-0.446	0.007
Low frequency	0.681	<0.0001
High frequency	0.294	0.08

HRV: Heart rate variability; IRLS: International Restless Legs Syndrome Study Group rating scale; pNN50: The proportion of adjacent RR intervals differing by >50 ms in the 24-hour recording; SDANN: The standard deviation of the average normal to normal intervals calculated over a 5-minute period of the entire electrocardiogram recording; SDNN: The standard deviation of all normal to normal intervals.

significantly greater LF power value and LF/HF ratio, which indicated elevated sympathetic nerve activity. It appeared that parasympathetic function was less compromised in RLS patients; the RMSSD, pNN50, and HF power, which reflect parasympathetic activity, were not significantly different between the 2 groups. Perhaps the most important distinguishing feature of the present study is the relationship between cardiac autonomic dysfunction and the severity of RLS symptoms.

HRV is a measure of continuous interplay between sympathetic and parasympathetic influences on heart rate. A high HRV is associated with good cardiovascular health and indicates a healthy heart that quickly responds to internal or external changes in a highly adaptive way. Several studies have demonstrated that a low HRV is associated with increased cardiovascular morbidity and mortality in both healthy individuals and those with coronary artery disease.<sup>[17,18]</sup> There are 2 different methods of HRV analysis: time domain and frequency domain analysis. In time domain analysis, the SDNN, SDANN, and SDNN index reflect overall variability, and the RMSSD and pNN50 estimate predominantly parasympathetic modulation. In frequency domain analysis, vagal tone is considered a major contributor to the HF component, and LF is believed to reflect both sympathetic and parasympathetic influences. Sympathovagal balance is frequently described using the LF/HF ratio.

The pathophysiology of RLS is unclear. The leading hypothesis for its pathogenesis is via a dopaminergic pathway, which suggests that there is a dopaminergic deficit in RLS. There are 4 main dopamine pathways in the brain: striatonigral, mesolimbic, mesocortical, and tuberoinfundibular. Dopaminergic neurons that originate in the cell group of A11 of the hypothalamus travel within the diencephalospinal dopaminergic pathway and innervate the lumbosacral cord, which modulates sensory and motor processes. Decreased activity of the A11 neuronal group causes increased sympathetic outflow to the periphery, changes the sensory information returned to the spinal cord, and results in paraesthesia perceived at the cortical level.<sup>[19]</sup> It has been demonstrated that stereotaxic bilateral 6-hydroxydopamine lesions into the A11 nucleus in rats resulted in behaviors consistent with RLS.<sup>[20]</sup> In addition, there is a well-known association between iron deficiency and RLS. Iron is an essential co-factor for tyrosine hydroxylase, which is rate-limiting enzyme in the synthesis of dopamine. Furthermore, D2 receptors contain iron atoms, which could explain why some RLS patients find relief with iron supplements.<sup>[21]</sup>

Several lines of evidence suggest that patients with RLS have autonomic system abnormalities. Symptoms related to the autonomic nervous system have been more frequently reported in patients with RLS.<sup>[8]</sup> It has been shown that men with RLS had higher rates of erectile dysfunction.<sup>[22]</sup> Autonomic responses to the head-up tilt test are blunted in patients with RLS during wakefulness.<sup>[23]</sup> There is also an increased prevalence of hypertension in patients with RLS, which is suggestive of autonomic dysfunction.<sup>[24]</sup>

The findings of our study were consistent with other studies that have reported cardiac autonomic dysfunction in RLS patients. Cikrikcioglu et al.<sup>[25]</sup> reported a higher erythrocyte sedimentation rate and mean platelet volume in RLS patients than in controls. They noted low HRV triangular index values, indicating elevated sympathetic myocardial activity. Bertisch et al.<sup>[26]</sup> studied 20 RLS patients without cardiovascular disease and 20 matched controls. The patients with RLS had a lower baroreflex gain, lower leg blood flow, and greater leg vascular resistance. As other indices of cardiovagal control, including respiratory sinus arrhythmia and Valsalva ratios, did not differ between the groups, they concluded that RLS patients had compromised cardiovagal control,

specific to the arterial baroreflex, potentially due to heightened sympathetic flow. The meaningful difference with our study was the existence of a relationship between the severity of RLS and HRV measures. The IRLS summed score was significantly correlated with LF power and negatively correlated with the SDNN, SDANN index, and pNN50. These findings suggested that the level of cardiac autonomic dysfunction was higher in more severely affected patients. During the study period, pharmacological treatment potentially affecting HRV was avoided and the patients were free of medication effects during ambulatory electrocardiogram monitoring.

An increase in sympathetic activity leads to an increase in heart rate as well as blood pressure, and is associated with increased cardiovascular morbidity and mortality. Sympathetic hyperactivity has been shown to contribute to endothelial damage and atherosclerosis. Sympathetic nerve hyperactivity may trigger ventricular arrhythmias.<sup>[27]</sup>

Decreased HRV is a risk factor for cardiovascular morbidity and mortality; therefore, the results of our study could be of importance to clinical practice.<sup>[28]</sup> Our research indicates that there is a relationship between RLS and increased sympathetic cardiac modulation. An adverse cardiovascular risk factor profile and increased activity of the sympathetic nervous system may contribute to an increased cardiovascular disease risk in patients with RLS.

# **Study limitations**

This was a retrospective analysis of data at a single center and the number of patients was small. Polysomnography was not used as a diagnostic tool. We assessed self-reported measures of sleep duration and quality, and therefore did not account for potential differences in objectively measured sleep. Follow-up assessments were not conducted and the results might not predict long-term outcomes.

## Conclusion

RLS is a neurological disorder that is associated with autonomic nervous system abnormalities. A decreased SDNN, SDANN, and SDNN index, and an increased LF power and LF/HF ratio may be the early signs of cardiac autonomic dysfunction in patients with RLS.

Peer-review: Externally peer-reviewed.

Conflict-of-interest: None.

Authorship contributions: Concept: A.Y., C.Y., A.K.; Design: A.Y., C.Y., A.K.; Supervision: A.Y., C.Y., A.K.; Materials: A.Y., C.Y., A.K.; Data: A.Y., C.Y., A.K.; Analysis: A.Y., C.Y., A.K.; Literature search: A.Y., C.Y., A.K.; Writing: A.Y., C.Y., A.K.; Critical revision: A.Y., C.Y., A.K.

#### REFERENCES

- 1. Willis T. De anima brutorum. London: Wells & Scott; 1672.
- Ekbom KA. Restless legs syndrome. Acta Med Scand 1945;158:4–122.
- Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd A. Pathophysiological concepts of restless legs syndrome. Mov Disord 2007;22:1451–6. [CrossRef]
- Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286–92. [CrossRef]
- García-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010;14:339–46.
- Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445–52. [CrossRef]
- Spolador T, Allis JC, Pondé MP. Treatment of restless legs syndrome. Rev Bras Psiquiatr 2006;28:308–15. [CrossRef]
- Shneyder N, Adler CH, Hentz JG, Shill H, Caviness JN, Sabbagh MN, et al Autonomic complaints in patients with restless legs syndrome. Sleep Med 2013;14:1413–6. [CrossRef]
- Ferini-Strambi L, Walters AS, Sica D. The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol 2014;261:1051–68. [CrossRef]
- Li Y, Walters AS, Chiuve SE, Rimm EB, Winkelman JW, Gao X. Prospective study of restless legs syndrome and coronary heart disease among women. Circulation 2012;126:1689–94.
- Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35–42. [CrossRef]
- Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354–81.
- Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, et al. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. J Am Coll Cardiol 2008;52:1353–65.
- Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956–62. [CrossRef]
- Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al; International Restless Legs

Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance. Sleep Med 2014;15:860–73. [CrossRef]

- 16. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121–32. [CrossRef]
- Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850–5. [CrossRef]
- Sandercock GR, Brodie DA. The role of heart rate variability in prognosis for different modes of death in chronic heart failure. Pacing Clin Electrophysiol 2006;29:892–904. [CrossRef]
- Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009;32:589–97.
- Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 2000;15:154–8. [CrossRef]
- 21. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22 Suppl 18:S440-8. [CrossRef]
- Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep 2010;33:75–9. [CrossRef]
- 23. Izzi F, Placidi F, Romigi A, Lauretti B, Marfia GA, Mercuri NB, et al. Is autonomic nervous system involved in restless legs syndrome during wakefulness? Sleep Med 2014;15:1392–7.
- Batool-Anwar S, Malhotra A, Forman J, Winkelman J, Li Y, Gao X. Restless legs syndrome and hypertension in middleaged women. Hypertension 2011;58:791–6. [CrossRef]
- Cikrikcioglu MA, Hursitoglu M, Erkal H, Kınas BE, Sztajzel J, Cakirca M, et al. Oxidative stress and autonomic nervous system functions in restless legs syndrome. Eur J Clin Invest 2011;41:734–42. [CrossRef]
- Bertisch SM, Muresan C, Schoerning L, Winkelman JW, Taylor JA. Impact of Restless Legs Syndrome on Cardiovascular Autonomic Control. Sleep 2016;39:565–71. [CrossRef]
- Volders PG. Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm 2010;7:1900–6. [CrossRef]
- Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. Circulation 1993;88:927–34. [CrossRef]

*Keywords:* Cardiac autonomic function; heart rate variability; restless leg syndrome.

Anahtar sözcükler: Kardiyak otonom fonksiyonlar; kalp hızı değişkenliği; huzursuz bacak sendromu.